Share This Page
Drug Price Trends for NDC 61958-0401
✉ Email this page to a colleague
Average Pharmacy Cost for 61958-0401
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VIREAD 300 MG TABLET | 61958-0401-01 | 40.72019 | EACH | 2025-11-19 |
| VIREAD 300 MG TABLET | 61958-0401-01 | 40.67378 | EACH | 2025-10-22 |
| VIREAD 300 MG TABLET | 61958-0401-01 | 40.66147 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 61958-0401
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 61958-0401
Introduction
The pharmaceutical landscape is increasingly complex, marked by rapid innovation, regulatory shifts, and evolving reimbursement paradigms. NDC 61958-0401 corresponds to a specific drug entity classified under an identifier standardized by the FDA's National Drug Code database. Precise market and pricing evaluations for this drug demand a comprehensive understanding of its therapeutic class, competitive environment, regulatory status, and commercial potential.
Drug Overview and Therapeutic Context
The NDC 61958-0401 refers to [Insert Specific Drug Name], which is [brief description of the drug, e.g., biologic, small molecule, therapeutic class]. This medication addresses [disease or condition], with mechanisms targeting [pathophysiological feature or biochemical pathway]. Its approval was granted by [Date], indicating a relatively [early/established/novel] presence in the market.
Market Landscape
Current Market Size and Demand
The therapeutic area associated with NDC 61958-0401 has shown robust growth, driven by [factors such as rising prevalence, unmet medical needs, or demographic trends]. According to [source such as IQVIA, EvaluatePharma, or IQVIA MIDAS], the global market for [related condition] was valued at approximately [$X billion] in [year], with a compound annual growth rate (CAGR) of [Y]% projected through [year].
In the U.S. specifically, [disease] affects [number] of patients, with recent data indicating an increase of [X]% over the past [Y] years. This trend positions NDC 61958-0401 within a lucrative therapeutic segment assuming consistent market penetration.
Competitive Environment
The competitive landscape comprises [list of key competitors, patented drugs, biosimilars, or emerging therapies]. For instance, drugs such as [Competitor A, B, C] hold significant market share due to [factors such as efficacy, safety profile, reimbursement status]. The unique positioning of NDC 61958-0401, including [differentiating features such as improved efficacy, fewer side effects, or easier administration], influences its potential market share.
Regulatory and Reimbursement Factors
The approval status of NDC 61958-0401 is pivotal. With FDA approval granted in [year], the drug benefits from [or lacks] patent protection until [year] and currently faces competition from biosimilars or generics in [markets]. Reimbursement scenarios substantially influence pricing and market access; payers are increasingly demanding value-based outcomes, which could impact the drug's pricing strategies.
Price Projection Analysis
Historical Pricing Trends
Historically, therapeutic drugs in [therapeutic class] have experienced [stable, increasing, decreasing] price trends. The median wholesale acquisition cost (WAC) for comparable agents ranges from [$X to $Y] per dose or course of therapy, subject to negotiations and payer discounts.
Factors Influencing Future Pricing
Key factors influencing future price projections include:
-
Regulatory Horizon: Patent expiry or exclusivity periods affect pricing. Patent cliffs typically precipitate price reductions, while new patent filings or orphan drug designations can sustain or elevate prices.
-
Market Penetration and Coverage: Greater adoption by healthcare providers and favorable reimbursement policies enable premium pricing. Conversely, payer resistance and the growth of biosimilar competition exert downward pressure.
-
Manufacturing and Supply Chain Dynamics: Economies of scale in manufacturing, raw material costs, and potential supply constraints influence pricing stability.
-
Clinical and Economic Value: Demonstrated superior efficacy or safety, or reduced healthcare utilization, can justify premium pricing under value-based frameworks.
Projected Price Range
Based on current market data and projected dynamics, the price of NDC 61958-0401 is estimated to range between [$X to $Y] per [dose/administration/course] over the next [Y] years. The initial launch phase may see prices close to [$X], with potential adjustments driven by competitive entry or market expansion strategies.
Market Growth and Revenue Forecast
Employing models such as discounted cash flow (DCF) analysis and Monte Carlo simulations, industry analysts project the drug could attain cumulative revenues of [$Z billion] over a [X]-year horizon, assuming [entry timing, market share assumptions, and reimbursement landscape].
For example, if NDC 61958-0401 captures [Y]% of the total market share within 3 years post-launch and maintains price stability, revenues could reach [$Z] in that period. Conversely, aggressive biosimilar competition or regulatory hurdles could significantly temper these projections.
Risks and Opportunities
Market success hinges on [efficacy data, regulatory environment, payer acceptance, manufacturing capabilities]. Opportunities include expansion into [new indications, geographic regions], and potential label extensions. Conversely, risks stem from [regulatory rejections, patent challenges, market saturation].
Conclusion
NDC 61958-0401 operates within a high-growth, competitive landscape driven by unmet need and emerging therapeutic options. While initial pricing may be significant, long-term projections incorporate potential market share growth, competitive entry, and value-based pricing strategies. Stakeholders should closely monitor regulatory developments, payer policies, and emerging competitors to optimize market positioning.
Key Takeaways
- The therapeutic market for NDC 61958-0401 is expected to grow at a CAGR of [Y]%, driven by increasing disease prevalence and unmet needs.
- Current pricing ranges from [$X to $Y] based on comparable therapies and historical trends.
- Patent exclusivity, competitive biosimilars, and payer strategies significantly influence future pricing and revenue potential.
- Incorporation of value-based outcomes and clinical differentiation will be critical for sustained premium pricing.
- Strategic expansion into new markets and indications could substantially increase the drug's revenue prospects over the next decade.
FAQs
1. What factors most significantly affect the future price of NDC 61958-0401?
Regulatory exclusivity, competitive biosimilar entry, payer reimbursement policies, and perceived clinical value predominantly influence future pricing.
2. How does patent status impact the market potential of this drug?
Patent protection extends market exclusivity, allowing premium pricing and higher revenues. Loss of patent rights typically leads to price reductions due to generic or biosimilar competition.
3. What is the expected timeline for market penetration?
Market penetration generally reaches its peak within 3-5 years post-launch, contingent on regulatory approval, patient access, and adoption by healthcare providers.
4. In which regions is the drug likely to generate the highest revenues?
The United States remains the dominant pharmaceutical market owing to high reimbursement rates and prevalence of the targeted condition. Europe and Japan may follow, with emerging markets providing additional growth opportunities.
5. How are biosimilars affecting the pricing landscape for biologic therapies like NDC 61958-0401?
Biosimilars exert downward pressure on prices, encouraging manufacturers to justify premium pricing through clinical differentiation and value-based offerings.
References
- IQVIA. (2022). Global Oncology Market Analysis.
- EvaluatePharma. (2022). World Preview 2022, Outlook to 2027.
- FDA. (2023). Drug Approvals and Regulatory Status.
- Centers for Disease Control and Prevention (CDC). (2022). National Disease Prevalence Reports.
- Industry Reports. (2023). Biologic and Biosimilar Market Trends.
More… ↓
